{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-024587","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2022-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.128110+00:00","generated_at":"2026-06-23T13:20:41.849586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology Q1 record revenue $13.7M (+22% YoY); adjusted EBITDA $450K","bullets":["Record quarterly revenue $13.7M, up 22% from $11.3M in prior year quarter.","Adjusted EBITDA $450K vs $422K; operating loss $284K includes $206K stock comp and $528K D&A.","Gross margin 49% vs 52% due to higher study expenses and SaaS costs; bookings at record level.","Cash $8.1M, no debt; net cash used in ops $195K, investing $754K for lab equipment.","Alloy Therapeutics partnership delivered series of antibody hits."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-024587","json":"https://secwatch.observer/filing/0001628280-22-024587.json","markdown":"https://secwatch.observer/filing/0001628280-22-024587.md","text":"https://secwatch.observer/filing/0001628280-22-024587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828022024587/0001628280-22-024587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828022024587/csbr-20220908.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T13:20:41.849586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}